Ask about this productRelated genes to: SLC18A1 antibody
- Gene:
- SLC18A1 NIH gene
- Name:
- solute carrier family 18 member A1
- Previous symbol:
- VMAT1, VAT1
- Synonyms:
- CGAT
- Chromosome:
- 8p21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-25
- Date modifiied:
- 2016-02-25
Related products to: SLC18A1 antibody
Related articles to: SLC18A1 antibody
- Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. The identification of effective molecular targets is crucial for advancing precision medicine and prognostic strategies. This study aims to uncover key CRC biomarkers through integrative bioinformatics analyses, providing mechanistic insights for therapeutic development. - Source: PubMed
Publication date: 2026/04/14
Pu GenyuanYin ZiZhang XinLiu ZhiqiYang CaitingXu ChunpingLai Mingming - Microsatellite instability (MSI) serves as a crucial biomarker for immune checkpoint blockade therapy in colorectal cancer (CRC). However, only around 40% of MSI CRC patients benefit from ICB. Investigating the mechanisms underlying MSI CRC, particularly its association with cell death and the immune microenvironment, can provide insights to improve immunotherapy efficacy. - Source: PubMed
Publication date: 2025/10/10
Qin YuanyuanZhou HongliZhu LingyanLi WentingJiang ZequnLi LiWu Mianhua - The hypothalamus belongs to the central brain structure designed for the neuroendocrine regulation of many organismal functions, including the stress response, cardiovascular system, and blood pressure, and it is well known that the serotonergic hypothalamic system plays a significant role in these processes. Unfortunately, the genetic determination of serotonergic hypothalamic mechanisms has been little studied. The aim of this article is to describe the expression profile of the genes in the hypothalamic serotonergic synapses in hypertensive ISIAH rats in comparison with normotensive WAG rats in control conditions and under the influence of a single short-term restraint stress. It was found that 14 differentially expressed genes (DEGs) may provide the inter-strain differences in the serotonergic synaptic function in the hypothalamus between the hyper- and normotensive rats studied. In hypertensive rats, downregulation of gene in the presynaptic serotoninergic ends and decreased expression of and genes determining the postsynaptic membrane conductance may be considered as a main factors causing differences in the function of hypothalamic serotoninergic synapses in hypertensive ISIAH and normotensive WAG rats at the basal conditions. Under basal conditions, glial cell genes were not involved in the formation of inter-strain differences in serotonergic synaptic function. The analysis of transcriptional responses to restraint stress revealed key genes whose expression is involved in the regulation of serotonergic signaling, and a cascade of interrelated changes in biological processes and metabolic pathways. Stress-dependent changes in the expression of some DEGs are similar in the hypothalamus of hypertensive and normotensive rats, but the expression of a number of genes changes in a strain-specific manner. The results suggest that in hypothalamic glial cells of both strains, restraint stress induces changes in the expression of DEGs associated with the synthesis of Ip3 and its receptors. Many of the identified serotonergic DEGs participate in the regulation of not only serotonergic synapses but may also be involved in the regulation of cholinergic, GABAergic, glutamatergic, and dopaminergic synapses. The results of the study provide new information on the genetic mechanisms of inter-strain differences in the functioning of the hypothalamic serotonergic system in hypertensive ISIAH and normotensive WAG rats at rest and under the influence of a single short-term restraint (emotional) stress. - Source: PubMed
Publication date: 2025/07/22
Redina Olga ERyazanova Marina AOshchepkov Dmitry YuMakovka Yulia VMarkel Arcady L - The progression of Parkinson's disease (PD) is influenced by genetic factors, particularly the Synuclein-Alpha (SNCA) gene, which encodes the alpha-synuclein (α-syn) protein involved in dopaminergic neuron degeneration. This study aimed to explore the relationship between rs356220 and PD risk and to understand its functional impact through computational analysis. We thoroughly reviewed nine databases regarding the association between this variant and PD risk. Firstly, a meta-analysis of 9 articles, consisting of 10 studies with 11,638 cases and 37,393 controls was conducted, that identified the C allele of rs356220 as a protective factor against PD (Odds Ratio (OR) 0.91, 95% Confidence Interval (CI): 0.88-0.94, P = 3.82E-08)). Subsequently, we characterized the functional impact of this non-coding variant in the pathophysiology of PD. In-silico process flow included transcription factor binding site (TFBS) analysis, pathway enrichment analysis, and protein interaction analysis. The TFBS analysis suggested that the C allele may influence multiple factors, while subsequent Pathway and Protein Network analyses identified proteins that enhance SNCA expression. Our investigation therefore reveals that rs356220 influences the dynamics of the α-syn protein through interactions with BAD, CANX, SLC18A1, and IRF1, potentially advancing the progression of PD. This research emphasizes the need for holistic study approaches to explore the intricacies of complex disorders like PD. - Source: PubMed
Publication date: 2025/07/02
Menon ShradhaRais Naushad - Bexarotene is a retinoid X receptor (RXR) pharmacological agonist that has been demonstrated to treat cutaneous T-cell lymphoma and promising therapeutic potential for neurological diseases. But it still remains unclear whether bexarotene participates in regulation of neuroblastoma. Human neuroblastoma SH-SY5Y cells were used as a model to investigate the neuronal differentiation impact of bexarotene. Bexarotene-cultured SH-SY5Y cells showed changes in cell morphology, adopting pyramidal shapes and extending neurites, increased expression of neuronal marker β-tubulin III and mature neurons marker neurofilament M and upregulation of neuronal differentiation markers including growth-associated protein 43 (GAP43) and synaptophysin (SYP). SH-SY5Y cells induced by bexarotene increased the expression of GABAergic marker glutamate decarboxylase (GAD1) and dopaminergic marker TH, but not glutamatergic marker glutamate-ammonia ligase (GLUL) and cholinergic marker solute carrier family 18 member 1 (SLC18A1). Functional enrichment analysis of RNAseq data and subsequent cell experiments revealed that the PI3K-Akt axis is the dominant signaling pathway promoting the differentiation of SH-SY5Y cells into mature and functional neurons in response to bexarotene. Additionally, we observed that SH-SY5Y cells show reduced proliferation rates accompanied by decreased expression of cyclin-dependent kinase 6 (CDK6) and increased expression of cyclin-dependent kinase 1 (CDK1) following 7-day exposure to bexarotene, suggesting bexarotene induces a quiescent state in SH-SY5Y cells. SH-SY5Y cells can be induced to mature neurons with decreased proliferation induced by bexarotene via PI3K-Akt axis. It indicates bexarotene has the potential to treat neuroblastoma. - Source: PubMed
Publication date: 2025/04/14
Zhang FanGao KaiZhang JunjiaoLi SihanLi YueWang JingminWu YeJiang YuwuWu Congying